People are likely to regain lost weight after stopping the medication, just as their blood pressure would increase if they stopped their anti-hypertensive medications, says Kushner
Cardiovascular benefit: In adults with type 2 diabetes who have established cardiovascular risk, a GLP-1 RA may provide cardiovascular benefit, independent of baseline A1C
And the avoidance of injection could improve adherence in long-term treatment protocols
Bariatric surgery remains the most effective intervention for severe obesity, producing 25% to 35% weight loss that's durable over years
[11] Long-term cardiometabolic safety data and dedicated cardiovascular outcome trial results are not yet available for retatrutide
People who have previously run GLP-1 based compounds and noticed post-cycle skin changes, either laxity or reduced firmness compared to their target weight look, are strong candidates for adding GHK-Cu to their next Retatrutide cycle